Reactivation of Hepatitis B Virus After Glioblastoma Treatment With Temozolomide -Case Report-
- 1 January 2011
- journal article
- case report
- Published by Japan Neurosurgical Society in Neurologia medico-chirurgica
- Vol. 51 (10), 728-731
- https://doi.org/10.2176/nmc.51.728
Abstract
A 61-year-old man with glioblastoma and positive for hepatitis B surface antigen (HBsAg) developed acute hepatitis due to hepatitis B virus (HBV) reactivation after concomitant postoperative treatment with temozolomide (75 mg/m2/day) and radiation therapy (60 Gy in 30 fractions). Corticosteroids were not used during chemo-radiation therapy, and grade 4 lymphocytopenia was observed. The levels of liver function tests (LFTs), including levels of aspartate aminotransferase and alanine aminotransferase, increased 5 weeks after the completion of chemo-radiation therapy, and reached the maximum levels of 1,549 IU/l (normal 13 to 33 IU/l) and 1,653 IU/l (normal 8 to 42 IU/l), respectively, after 2 weeks. At this point, serum HBV-deoxyribonucleic acid (DNA) level had increased to 630-fold over the baseline, and therapy with the antivirus agent entecavir (0.5 mg daily) was started. Over the next 2 weeks, the levels of LFTs and HBV-DNA improved. The present and previous cases suggest that grade 3/4 lymphocytopenia or grade 2 lymphocytopenia with corticosteroid use might have a significant effect on HBV reactivation. To avoid this complication, HBsAg-positive patients with glioblastoma should consult a hepatologist for initiating antivirus therapy before temozolomide treatment.Keywords
This publication has 13 references indexed in Scilit:
- Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection: Joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral HepatitisKanzo, 2009
- Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and managementInternal Medicine Journal, 2007
- Fatal Reactivation of Hepatitis B with TemozolomideNew England Journal of Medicine, 2007
- Hepatitis B reactivation during glioblastoma treatment with temozolomide: A cautionary noteNeurology, 2007
- Selective Lymphopenia and Opportunistic Infections in Neuroendocrine Tumor Patients Receiving TemozolomideCancer Investigation, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Agranulocytosis Associated with Initiation of Famotidine TherapyAnnals of Pharmacotherapy, 2002
- Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trialsCancer Treatment Reviews, 1997
- Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: Survey in Japan, 1987-1991Cancer, 1996
- Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapyGastroenterology, 1991